APLS Apellis Pharmaceuticals Inc

$27.35

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.

Website: https://apellis.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1492422
Address
6400 WESTWIND WAY, SUITE A, CRESTWOOD, KY, US
Valuation
Market Cap
$2.28B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
10.00
Performance
EPS
$-1.60
Dividend Yield
—
Profit Margin
-25.30%
ROE
-93.50%
Technicals
50D MA
$24.37
200D MA
$30.88
52W High
$50.98
52W Low
$17.48
Fundamentals
Shares Outstanding
126M
Target Price
$42.35
Beta
0.84

APLS EPS Estimates vs Actual

● Estimated
● Actual

APLS News & Sentiment

Jul 31, 2025 • Benzinga BULLISH
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , AGCO ( NYSE:AGCO )
U.S. stocks were higher, with the Nasdaq Composite gaining around 150 points on Thursday. Shares of Roblox Corporation RBLX rose sharply during Thursday's session after the company reported better-than-expected second-quarter sales results and raised its FY25 sales guidance.
Jul 31, 2025 • GlobeNewswire NEUTRAL
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
Jul 29, 2025 • Benzinga SOMEWHAT-BULLISH
FDA Approves Apellis' Empaveli, Marks Key Milestone - Apellis Pharmaceuticals ( NASDAQ:APLS )
Empaveli cut proteinuria by 68% in C3G and IC-MPGN patients in a six-month trial. 71% of patients on Empaveli had complete clearance of C3 deposits. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.
Jul 28, 2025 • Benzinga NEUTRAL
FDA Approves Apellis' EMPAVELI® ( pegcetacoplan ) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older - Apellis Pharmaceuticals ( NASDAQ:APLS )
Proven efficacy across all three key markers of disease-68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence
Jul 28, 2025 • GlobeNewswire NEUTRAL
FDA Approves Apellis' EMPAVELI® ( pegcetacoplan ) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass., July 28, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved EMPAVELI® ( pegcetacoplan ) as the first treatment for C3 glomerulopathy ( C3G ) or primary immune complex ...
Jul 28, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Axsome Therapeutics ( AXSM ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sentiment Snapshot

Average Sentiment Score:

0.136
50 articles with scored sentiment

Overall Sentiment:

Neutral

APLS Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.54
  • Whisper: —
  • Surprise %: 0.0%
Feb 25, 2025
Dec 31, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.29
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 27.8%
Nov 05, 2024
Sep 30, 2024 (Pre market)
-0.16 Surprise
  • Reported EPS: $-0.46
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: -54.1%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.32
  • Whisper: —
  • Surprise %: 12.5%
May 07, 2024
Mar 31, 2024 (Pre market)
0.05 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.47
  • Whisper: —
  • Surprise %: 10.6%
Feb 27, 2024
Dec 31, 2023 (Pre market)
-0.04 Surprise
  • Reported EPS: $-0.73
  • Estimate: $-0.69
  • Whisper: —
  • Surprise %: -5.8%
Nov 01, 2023
Sep 30, 2023 (Pre market)
-0.31 Surprise
  • Reported EPS: $-1.17
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -36.0%
Jul 31, 2023
Jun 30, 2023 (Pre market)
0.3 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-1.32
  • Whisper: —
  • Surprise %: 22.7%
May 04, 2023
Mar 31, 2023 (Post market)
-0.1 Surprise
  • Reported EPS: $-1.56
  • Estimate: $-1.46
  • Whisper: —
  • Surprise %: -6.8%

Financials